Clinical Trials Logo

Rituximab clinical trials

View clinical trials related to Rituximab.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05734794 Recruiting - Clinical trials for Nephrotic Syndrome in Children

Study of Rituximab Monotherapy on Children With New-onset Nephrotic Syndrome: A Randomized Controlled Trial

STORM
Start date: February 9, 2023
Phase: Phase 3
Study type: Interventional

The main objective is to evaluate the effectiveness of Rituximab monotherapy versus steroid therapy on children with new-onset nephrotic syndrome within the 52-week follow-up.

NCT ID: NCT05332587 Recruiting - Rituximab Clinical Trials

Efficacy and Safety of Low-dose Rituximab in the Treatment of Refractory Myasthenia Gravis

Start date: August 1, 2020
Phase: Phase 3
Study type: Interventional

This study is designed to evaluate the effectiveness and safety of low-dose rituximab in patients with refractory myasthenia gravis. The traditional treatment of MG is immunosuppressive therapy, usually beginning with corticosteroids. However, up to 70% of treated patients show an incomplete response, including 10 - 30% who are unresponsive. Corticosteroids and other immunosuppressive therapies presented also many side effects. The investigators propose to evaluate in a pilot, open, prospective, single central study, the interest of rituximab (RTX) in the treatment of patients with refractory MG. Fifty patients with refractory MG will be included in the study and divided into two stages: 14 patients in the first stage were followed up after using RTX according to the study protocol. The study will move into the second stage on if the number of effective cases is greater than 3, otherwise, the study will be discontinued (based on Simon's Optimal Two-stage Design). The remaining 36 patients were enrolled in the second stage. In the first and second stages, the treatment plan and follow-up plan were consistent. The therapeutical schema is rituximab 100-200 mg/week for a total of 2-4 times, followed by adequate organ function, laboratory parameters and assessment of MG after each injection and end of follow up for 24 weeks.

NCT ID: NCT04877496 Recruiting - Immunosuppression Clinical Trials

Responses to COVID19 Vaccination in Patients With a Treatment History of Rituximab.

RituxiVac
Start date: April 26, 2021
Phase:
Study type: Observational [Patient Registry]

Patients with treatment history of rituximab since 01.01.2019 and immunocompetent volunteers will be contacted to give a blood sample after their COVID19 vaccination, and in a subset also before vaccination. Immune responses of antibodies and SARS-CoV2-specific T-cells to the vaccination will be quantified and the rituximab effect on COVID19 vaccine-induced immune responses is analyzed.

NCT ID: NCT03958916 Recruiting - Clinical trials for Lymphoma, Non-Hodgkin

Prospective Multicenters Clinical Cohort Study of Stratified Treatment of Chinese Children With BL/DLBCL

Start date: May 5, 2017
Phase:
Study type: Observational [Patient Registry]

The trial SCCCG-BL/DLBCL-2017 is a collaborative prospective, multicenters, non-randomized, observational, cohort clinical study with participating centers of the South China Children's Cancer Group-Non-Hodgkin lymphoma group(SCCCG-NHL). The aim of the study is to evaluate efficacy and safety of stratified treatment based on risk factors of childhood and adolescents Burkitt lymphoma(BL)/diffuse large B-cell lymphoma(DLBCL) patients in china.

NCT ID: NCT03373019 Recruiting - Neoplasms Clinical Trials

Chidamide Combined With R-GDP in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Start date: December 21, 2017
Phase: Phase 2
Study type: Interventional

The goal of this clinical trial is to evaluate therapeutic efficacy of Chidamide combined with R-GDP (rituximab/gemcitabine/dexamethasone/cisplatin)in treating Patients with relapsed or refractory Diffuse Large B-cell Lymphoma (DLBCL) not suitable for transplantation.